Orotate phosphoribosyltransferase as a predictor of benefit from S-1 adjuvant chemotherapy for cholangiocarcinoma patients.

Keiichi AkahoshiDaisuke BanRyo KubokiAtsushi ObaHiroaki OnoYusuke MitsunoriAtsushi KudoShinji TanakaMinoru Tanabe

Published in: Journal of gastroenterology and hepatology (2018)

Cholangiocarcinoma patients with high OPRT expression would benefit from postoperative adjuvant S-1 therapy, which increases the DFS. Assessment of OPRT expression may contribute to the optimization of adjuvant chemotherapy for cholangiocarcinoma.

Keyphrases

poor prognosis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
binding protein
patients undergoing
prognostic factors
patient reported
replacement therapy